SCHEMBL4241978

SCHEMBL4241978

CCC(CC)NC(=O)Nc1ccc(Oc2ccc(N(CC)C(=O)c3ccc(OC45CCCC(CC4)N5C)cc3)cc2)c(OC)c1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.36
MCHR1 Q99705 5/20 0.36
TAS1R3 Q7RTX0 1/20 0.36
TAS1R1 Q7RTX1 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
MAPT P10636 3/20 0.34
LPAR1 Q92633 1/20 0.33
LPAR5 Q9H1C0 1/20 0.33
MEN1 O00255 2/20 0.32
GAA P10253 2/20 0.32
KMT2A Q03164 2/20 0.32
ALDH1A1 P00352 2/20 0.32
HTT P42858 1/20 0.32
FGFR1 P11362 1/20 0.32
KIT P10721 1/20 0.32
PDGFRA P16234 1/20 0.32
KDM4E B2RXH2 1/20 0.32
HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4233732 0.95 MCHR1 (0.35) PKMMCHR1TAS1R3TAS1R1SMN1; SMN2
SCHEMBL4239122 0.94 PKM (0.33) PKMMCHR1TAS1R3TAS1R1MAPT
SCHEMBL4242456 0.93 PKM (0.37) PKMMCHR1TAS1R3TAS1R1SMN1; SMN2
SCHEMBL4228160 0.93 MCHR1 (0.34) PKMMCHR1TAS1R3TAS1R1SMN1; SMN2
SCHEMBL4237948 0.93 MCHR1 (0.34) PKMMCHR1TAS1R3TAS1R1SMN1; SMN2
SCHEMBL4231908 0.92 ALDH1A1 (0.34) PKMTAS1R3TAS1R1NPSR1MAPT
SCHEMBL4229247 0.89 MCHR1 (0.45) PKMMCHR1TAS1R3TAS1R1SMN1; SMN2
SCHEMBL4238808 0.85 MCHR1 (0.42) PKMMCHR1TAS1R3TAS1R1SMN1; SMN2
SCHEMBL4226989 0.83 TAS1R3 (0.39) PKMMCHR1TAS1R3TAS1R1SMN1; SMN2
SCHEMBL4232426 0.83 MCHR1 (0.40) PKMMCHR1TAS1R3TAS1R1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US claimed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 EP claimed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 WO claimed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R PKM 1734/4885MCHR1 47/4885TAS1R3 1436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.